{"contentid": 488034, "importid": NaN, "name": "Swedish firm breaking new ground in rare kidney condition", "introduction": "Stockholm\u00e2\u0080\u0099s Calliditas Therapeutics has completed its US regulatory submission for Nefecon (budesonide), an oral treatment for primary IgA Nephropathy (IgAN).", "content": "<p>Stockholm&rsquo;s Calliditas Therapeutics (Nasdaq: CALT) has completed its US regulatory submission for Nefecon (budesonide), an oral treatment for primary IgA Nephropathy (IgAN).</p>\n<p>The Swedish firm is seeking an Accelerated Approval from the Food and Drug Administration for the novel formulation, which targets down regulation of IgA, and plans to submit for European marketing authorization imminently.</p>\n<p>The European Medicines Agency has indicated that it would be open to reviewing a submission under the similar Conditional Marketing Authorization scheme, based on the firm&rsquo;s trial program.</p>\n<p>Calliditas is seeking approval based on positive data from the Phase III NefIgArd trial, announced late last year, which showed a statistically-significant reduction in proteinuria compared with placebo.</p>\n<p>Subject to regulatory approval, Calliditas plans to commercialize the product by itself in the USA, and through collaborations in other regions.</p>\n<h2>Nefecon development</h2>\n<p>With no currently-approved drugs for IgAN, the Swedish firm is well-placed to fill a significant unmet clinical need, particularly as new clinical endpoints have shortened lead times for development.</p>\n<p>Around half of people with IgAN - up to 200,000 in the USA and Europe - are at risk of disease progression, which can lead to the highly burdensome treatments of dialysis and transplantation.</p>\n<p>In this context, analysts have forecast that Nefecon, a patient-friendly oral treatment, could have global blockbuster potential, with peak sales in excess of $1 billion.</p>\n<p>Commenting on the US FDA submission, chief executive Ren&eacute;e Aguiar-Lucander said: &ldquo;This is the first time a drug specifically designed for IgAN is being submitted for approval to the FDA and I believe that we are delivering a very robust data package based on the successful outcome of our pivotal Phase III trial and our large Phase IIb trial, which also met both the primary and key secondary endpoints.&rdquo;</p>\n<p>A confirmatory study designed to provide data on long-term renal benefit is fully recruited and is expected to read out in early 2023.</p>", "date": "2021-03-15 10:27:00", "meta_title": NaN, "meta_keywords": "IgAN, Calliditas, submission, Nefecon, firm, regulatory, treatment, oral, approval, primary, trial, Swedish, condition, kidney, rare, ground, breaking, dat", "meta_description": "Stockholm\u00e2\u0080\u0099s Calliditas Therapeutics has completed its US regulatory submission for Nefecon (budesonide), an oral treatment of primary IgA Nephropathy (IgAN).", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-15 10:07:37", "updated": "2021-03-15 10:29:43", "access": NaN, "url": "https://www.thepharmaletter.com/article/swedish-firm-breaking-new-ground-in-rare-kidney-condition", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "calliditas_large.png", "image2id": "calliditas_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Nephrology and Hepatology, Rare diseases", "topic_tag": "Drug Trial, Focus On, Regulation, Research, US FDA", "geography_tag": "Sweden, USA", "company_tag": "Calliditas Therapeutics", "drug_tag": "Nefecon", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-15 10:27:00"}